Montelukast


Generic Medicine Info
Special Precautions
Aspirin-sensitive asthmatic patient must continue avoiding aspirin and other NSAIDs. Not intended for treatment of acute asthma attacks. Not recommended as monotherapy in treatment of moderate chronic asthma. Avoid abrupt substitution to oral or inhaled corticosteroids. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness or drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs and symptoms of behavioural changes.
Adverse Reactions
Significant: Behavioural changes (e.g. agitation, anxiety, depression, dream abnormalities, obsessive-compulsive disorder). Rarely, systemic eosinophilia, vasculitis with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ear and labyrinth disorders: Otalgia, otitis media. Eye disorders: Myopia, conjunctivitis. Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain, dyspepsia, gastroenteritis. General disorders and administration site conditions: Pyrexia. Infections and infestations: Viral infection, tooth infection. Investigations: Elevated serum transaminase levels (ALT, AST). Nervous system disorders: Headache, drowsiness, dizziness. Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, cough, acute bronchitis, influenza, laryngitis, pharyngitis, rhinorrhoea, sinusitis, sinus headache, pneumonia. Skin and subcutaneous tissue disorders: Rash, eczema or atopic dermatitis, skin infection, urticaria. Vascular disorders: Epistaxis.
Drug Interactions
Decreased plasma concentration with CYP450 inducers (e.g. phenytoin, phenobarbital, rifampicin). Gemfibrozil may increase montelukast serum concentration.
ATC Classification
R03DC03 - montelukast ; Belongs to the class of leukotriene receptor antagonists. Used in the systemic treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on montelukast from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in